Literature DB >> 25799890

Live donor liver transplantation: a valid alternative for critically ill patients suffering from acute liver failure.

N Goldaracena1, V N Spetzler1, M Marquez1, N Selzner2, M S Cattral1, P D Greig1, L Lilly2, I D McGilvray1, G A Levy2, A Ghanekar1, E L Renner2, D R Grant1, M Selzner1.   

Abstract

We report the outcome of live donor liver transplantation (LDLT) for patients suffering from acute liver failure (ALF). From 2006 to 2013, all patients with ALF who received a LDLT (n = 7) at our institution were compared to all ALF patients receiving a deceased donor liver transplantation (DDLT = 26). Groups were comparable regarding pretransplant ICU stay (DDLT: 1 [0-7] vs. LDLT: 1 days [0-10]; p = 0.38), mechanical ventilation support (DDLT: 69% vs. LDLT: 57%; p = 0.66), inotropic drug requirement (DDLT: 27% vs. LDLT: 43%; p = 0.64) and dialysis (DDLT: 2 vs. LDLT: 0 patients; p = 1). Median evaluation time for live donors was 24 h (18-72 h). LDLT versus DDLT had similar incidence of overall postoperative complications (31% vs. 43%; p = 0.66). No difference was detected between LDLT and DDLT patients regarding 1- (DDLT: 92% vs. LDLT: 86%), 3- (DDLT: 92% vs. LDLT: 86%), and 5- (DDLT: 92% vs. LDLT: 86%) year graft and patient survival (p = 0.63). No severe donor complication (Dindo-Clavien ≥3 b) occurred after live liver donation. ALF is a severe disease with high mortality on liver transplant waiting lists worldwide. Therefore, LDLT is an attractive option since live donor work-up can be expedited and liver transplantation can be performed within 24 h with excellent short- and long-term outcomes. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research / practice; donors and donation: living; fulminant hepatic failure; liver transplantation / hepatology; liver transplantation: living donor

Mesh:

Year:  2015        PMID: 25799890     DOI: 10.1111/ajt.13203

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

Review 1.  Liver Transplantation in India: At the Crossroads.

Authors:  Sanjay Nagral; Aditya Nanavati; Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

Review 2.  The care of donors and recipients in adult living donor liver transplantation.

Authors:  A Hendrickse; J Ko; T Sakai
Journal:  BJA Educ       Date:  2022-08-23

Review 3.  Right lobe living-donor hepatectomy-the Toronto approach, tips and tricks.

Authors:  Gonzalo Sapisochin; Nicolas Goldaracena; Jerome M Laurence; Gary A Levy; David R Grant; Mark S Cattral
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

4.  Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience.

Authors:  Andrew S Barbas; Nicolas Goldaracena; Martin J Dib; David P Al-Adra; Aloysious D Aravinthan; Leslie B Lilly; Eberhard L Renner; Nazia Selzner; Mamatha Bhat; Mark S Cattral; Anand Ghanekar; Ian D McGilvray; Gonzalo Sapisochin; Markus Selzner; Paul D Greig; David R Grant
Journal:  Transplant Direct       Date:  2017-05-10

Review 5.  Beyond KCH selection and options in acute liver failure.

Authors:  William Bernal; Roger Williams
Journal:  Hepatol Int       Date:  2018-06-01       Impact factor: 6.047

6.  Role of serum levels of intraoperative brain natriuretic peptide for predicting acute kidney injury in living donor liver transplantation.

Authors:  Min Suk Chae; Hyunjoon Park; Ho Joong Choi; Misun Park; Hyun Sik Chung; Sang Hyun Hong; Chul Soo Park; Jong Ho Choi; Hyung Mook Lee
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

7.  Expanding the donor pool: Donation after circulatory death and living liver donation do not compromise the results of liver transplantation.

Authors:  Dagmar Kollmann; Gonzalo Sapisochin; Nicolas Goldaracena; Bettina E Hansen; Ramraj Rajakumar; Nazia Selzner; Mamatha Bhat; Stuart McCluskey; Mark S Cattral; Paul D Greig; Les Lilly; Ian D McGilvray; Anand Ghanekar; David R Grant; Markus Selzner
Journal:  Liver Transpl       Date:  2018-05-14       Impact factor: 5.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.